This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It notes that abnormalities in mineral metabolism are common even in early stages of CKD and accelerate with worsening kidney function. The factors involved in secondary hyperparathyroidism pathogenesis are described. Different types of renal osteodystrophy are defined based on laboratory abnormalities and presence of bone disease and soft tissue calcification. The document also outlines clinical manifestations of renal osteodystrophy including bone pain, fractures, and tendon ruptures.
CKD-MBD is a systemic disorder seen in progressive kidney disease characterized by abnormalities in calcium, phosphorus, PTH, and vitamin D levels as well as bone abnormalities and soft tissue calcification. Key aspects of CKD-MBD include impaired regulation of phosphorus and calcium leading to elevated levels that stimulate PTH production and reduced vitamin D activation. This disrupts bone and mineral homeostasis and increases cardiovascular risks. Treatment involves controlling levels through diet, phosphate binders, vitamin D, and PTH therapies according to KDIGO guidelines.
This document discusses chronic kidney disease mineral and bone disorder (CKD-MBD). It begins by defining CKD-MBD and describing the pathogenesis involving abnormalities in calcium, phosphorus, PTH, and vitamin D metabolism. It then discusses the clinical features, investigations, and laboratory target levels. The final section covers treatment approaches including dietary phosphorus restriction, phosphate binders, vitamin D analogs, and calcimimetics to manage secondary hyperparathyroidism and hyperphosphatemia. It also addresses treating adynamic bone disease.
This document presents guidelines from Kidney Disease: Improving Global Outcomes (KDIGO) for the diagnosis, evaluation, prevention and treatment of chronic kidney disease - mineral and bone disorder (CKD-MBD). KDIGO is an independent nonprofit foundation that develops clinical practice guidelines to improve care for kidney disease patients worldwide. The guidelines were developed by an international work group and evidence review team using the GRADE framework. The guidelines cover diagnosis of CKD-MBD through biochemical abnormalities, bone changes, and vascular calcification, as well as treatment targeting phosphorus, PTH levels, bone, and kidney transplant bone disease.
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBDAbdullah Ansari
Introduction and definition of CKD–MBD
Diagnosis of CKD–MBD: biochemical abnormalities
Diagnosis of CKD–MBD: bone
Diagnosis of CKD–MBD: vascular calcification
Treatment of CKD–MBD targeted at serum phosphorus and serum calcium
Treatment of abnormal PTH levels in CKD–MBD
Treatment of bone with bisphosphonates, other osteoporosis medications and growth hormone
Evaluation and treatment of kidney transplant bone disease
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/AtiaKPIdzAQ
Arabic Language version of this lecture is available at:
https://youtu.be/2cwyPcRDGEY
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Chronic kidney disease-mineral bone disorder (CKD-MBD) is a common complication in chronic kidney disease caused by reduced kidney function and mineral metabolism abnormalities. This leads to high phosphate, activation of parathyroid hormone, and bone abnormalities from renal osteodystrophy to vascular calcification. Treatment focuses on controlling phosphate levels through binders like sevelamer and cinacalcet to reduce parathyroid hormone in order to prevent bone disease and fractures while minimizing cardiovascular risks.
1) Coronary artery calcification is significant and progressive in a majority of patients with early chronic kidney disease. There is an association between arterial calcification and increased risk of all-cause mortality in chronic kidney disease patients on dialysis.
2) While the data are not entirely consistent, some studies have found relatively less progression of vascular calcification with sevelamer versus calcium-containing phosphate binders among patients with chronic kidney disease.
3) One randomized controlled trial found that among hemodialysis patients treated with either calcium acetate or sevelamer for 1 year, there was similar progression of coronary artery calcification with intensive lowering of LDL-C levels in both groups.
Dr. Ahmed Mohamed Albeyaly is a nephrology specialist and moderator in Dakahlia Health directorate. The document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD), which is a systemic disorder affecting bone disease, soft tissue calcification, and abnormalities in mineral metabolism that result from kidney disease and kidney failure. The document covers pathogenesis of CKD-MBD, classifications of bone disease seen in CKD patients, diagnosis through laboratory tests and imaging, and treatment approaches including controlling calcium, phosphorus, PTH, and vitamin D levels.
CKD-MBD is a systemic disorder seen in progressive kidney disease characterized by abnormalities in calcium, phosphorus, PTH, and vitamin D levels as well as bone abnormalities and soft tissue calcification. Key aspects of CKD-MBD include impaired regulation of phosphorus and calcium leading to elevated levels that stimulate PTH production and reduced vitamin D activation. This disrupts bone and mineral homeostasis and increases cardiovascular risks. Treatment involves controlling levels through diet, phosphate binders, vitamin D, and PTH therapies according to KDIGO guidelines.
This document discusses chronic kidney disease mineral and bone disorder (CKD-MBD). It begins by defining CKD-MBD and describing the pathogenesis involving abnormalities in calcium, phosphorus, PTH, and vitamin D metabolism. It then discusses the clinical features, investigations, and laboratory target levels. The final section covers treatment approaches including dietary phosphorus restriction, phosphate binders, vitamin D analogs, and calcimimetics to manage secondary hyperparathyroidism and hyperphosphatemia. It also addresses treating adynamic bone disease.
This document presents guidelines from Kidney Disease: Improving Global Outcomes (KDIGO) for the diagnosis, evaluation, prevention and treatment of chronic kidney disease - mineral and bone disorder (CKD-MBD). KDIGO is an independent nonprofit foundation that develops clinical practice guidelines to improve care for kidney disease patients worldwide. The guidelines were developed by an international work group and evidence review team using the GRADE framework. The guidelines cover diagnosis of CKD-MBD through biochemical abnormalities, bone changes, and vascular calcification, as well as treatment targeting phosphorus, PTH levels, bone, and kidney transplant bone disease.
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBDAbdullah Ansari
Introduction and definition of CKD–MBD
Diagnosis of CKD–MBD: biochemical abnormalities
Diagnosis of CKD–MBD: bone
Diagnosis of CKD–MBD: vascular calcification
Treatment of CKD–MBD targeted at serum phosphorus and serum calcium
Treatment of abnormal PTH levels in CKD–MBD
Treatment of bone with bisphosphonates, other osteoporosis medications and growth hormone
Evaluation and treatment of kidney transplant bone disease
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/AtiaKPIdzAQ
Arabic Language version of this lecture is available at:
https://youtu.be/2cwyPcRDGEY
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Chronic kidney disease-mineral bone disorder (CKD-MBD) is a common complication in chronic kidney disease caused by reduced kidney function and mineral metabolism abnormalities. This leads to high phosphate, activation of parathyroid hormone, and bone abnormalities from renal osteodystrophy to vascular calcification. Treatment focuses on controlling phosphate levels through binders like sevelamer and cinacalcet to reduce parathyroid hormone in order to prevent bone disease and fractures while minimizing cardiovascular risks.
1) Coronary artery calcification is significant and progressive in a majority of patients with early chronic kidney disease. There is an association between arterial calcification and increased risk of all-cause mortality in chronic kidney disease patients on dialysis.
2) While the data are not entirely consistent, some studies have found relatively less progression of vascular calcification with sevelamer versus calcium-containing phosphate binders among patients with chronic kidney disease.
3) One randomized controlled trial found that among hemodialysis patients treated with either calcium acetate or sevelamer for 1 year, there was similar progression of coronary artery calcification with intensive lowering of LDL-C levels in both groups.
Dr. Ahmed Mohamed Albeyaly is a nephrology specialist and moderator in Dakahlia Health directorate. The document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD), which is a systemic disorder affecting bone disease, soft tissue calcification, and abnormalities in mineral metabolism that result from kidney disease and kidney failure. The document covers pathogenesis of CKD-MBD, classifications of bone disease seen in CKD patients, diagnosis through laboratory tests and imaging, and treatment approaches including controlling calcium, phosphorus, PTH, and vitamin D levels.
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It defines CKD-MBD as a systemic disorder caused by CKD that is characterized by abnormalities in mineral metabolism, bone disease, and soft tissue calcification. The document outlines the classification of CKD-MBD and renal osteodystrophy based on abnormalities in laboratory values, bone disease, and calcification. It also discusses the pathophysiology and diagnosis of renal osteodystrophy using bone biopsy and biomarkers. Imaging techniques for evaluating vascular calcification are presented along with the ongoing challenges in diagnosing and monitoring CKD-MBD.
The document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It defines CKD-MBD and explains that it involves abnormalities in calcium, phosphorus, PTH, FGF23, and vitamin D metabolism as well as bone abnormalities and extraskeletal calcification. The document then discusses the pathogenesis of CKD-MBD, including hypocalcemia, phosphate retention, decreased calcitriol activity, FGF23, secondary hyperparathyroidism, tertiary hyperparathyroidism, and skeletal resistance to PTH. It also describes bone diseases associated with CKD-MBD including osteitis fibrosa, adynamic bone disease, osteomalacia, mixed uremic osteod
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It begins with an overview of the key components involved in CKD-MBD, including calcium, phosphorus, parathyroid hormone, vitamin D, fibroblast growth factor 23, and magnesium. The document then presents two clinical cases involving patients with CKD and discusses treatment options based on their lab results. It also covers the roles of vitamin D and magnesium in vascular pathology and mortality in CKD patients. Guidelines for the treatment of secondary hyperparathyroidism from KDIGO are also summarized.
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It defines CKD-MBD and renal osteodystrophy. It notes that CKD-MBD is characterized by abnormalities in calcium, phosphorus, PTH, or vitamin D metabolism. It also discusses secondary hyperparathyroidism in CKD and characteristics of major CKD-related bone diseases. The document then presents two patient case studies and questions related to interpreting lab results and determining appropriate treatment steps for managing mineral and bone disorders in the patients.
The pathogenesis of CKD-MBD is complex, involving disruptions in mineral homeostasis and hormone levels as kidney function declines. Key factors include hyperphosphatemia, decreased calcitriol levels, and hypocalcemia. This leads to elevated PTH levels as the parathyroid glands respond to low calcium and calcitriol. Over time, the parathyroid glands become resistant due to downregulation of receptors. Progressive CKD also impairs the kidneys' ability to regulate phosphate, exacerbating hyperphosphatemia and CKD-MBD.
Mineral and Bone Disorder in Chronic Kidney Diseasedrsampadasinha
This document summarizes chronic kidney disease-mineral and bone disorder (CKD-MBD), including its definition, pathogenesis, diagnosis, and management recommendations. Specifically:
- CKD-MBD is defined as a systemic disorder involving abnormalities in calcium, phosphorus, vitamin D, PTH, and bone. It can cause skeletal and extraskeletal complications.
- As kidney function declines, abnormalities in mineral metabolism develop, leading to high or low bone turnover diseases. Phosphate retention, low calcitriol, and parathyroid gland changes drive secondary hyperparathyroidism.
- Diagnosis involves monitoring mineral levels and PTH. Bone biopsy determines the type of renal osteodystrophy
This document discusses bone and mineral disease in patients with chronic kidney disease. Key points:
1) Patients with chronic kidney disease often develop metabolic bone disease due to abnormalities in calcium, phosphorus, vitamin D, and parathyroid hormone levels. This can lead to bone abnormalities like osteitis fibrosa or adynamic bone.
2) Secondary hyperparathyroidism is common, driven by phosphorus retention, low vitamin D, and decreased calcium sensing by the parathyroid glands. High PTH then causes high bone turnover.
3) In addition to bone effects, extraskeletal calcification can occur in blood vessels, skin, and other tissues in patients with kidney disease. Care involves monitoring mineral
This document discusses anemia in chronic kidney disease (CKD). It outlines the benefits of treating anemia, including improved quality of life and reduced cardiovascular risks. It then presents a case study of a 65-year-old CKD patient with diabetes and hypothyroidism. His lab results show hemoglobin of 8.4 g/dL, ferritin of 950 ng/mL, and TSAT of 15%. The document goes on to discuss factors contributing to anemia, methods of assessing iron status, iron replacement therapies including oral and parenteral options, ESA therapies, and guidelines around hemoglobin targets in CKD patients. Safety issues of iron treatment and limitations of ESA therapy are also reviewed.
What are we missing in CKD-MBD management? - prof. Magdy El SharkawyMNDU net
This document discusses gaps in the current definitions and management of chronic kidney disease-mineral and bone disorder (CKD-MBD). It notes that while CKD-MBD is now defined more broadly than just renal osteodystrophy, clinical definitions are still lacking. Guidelines for phosphorus management need clarification on organic vs. inorganic phosphorus and dialysate calcium guidelines could be more precise. Role of magnesium and biomarkers like alkaline phosphatase are underexplored. PTH assays and their relationship to bone remodeling is also in need of better definition. Overall, this highlights several areas where CKD-MBD understanding and treatment could be improved.
Anaemia of chronic kidney disease GUIDELINES TO PRACTICE 2013Ayman Seddik
1) Anaemia is common in chronic kidney disease (CKD) due to reduced kidney function and erythropoietin production. It can cause lower quality of life and increased risk of cardiovascular complications.
2) Guidelines recommend diagnosing anaemia of CKD in adults with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 and hemoglobin ≤11 g/dL.
3) Treatment involves iron supplementation and erythropoiesis-stimulating agents (ESAs) to increase hemoglobin levels, with a target range of 11-12 g/dL according to recent guidelines. Higher targets may increase risk without clear benefits.
This document discusses anemia in chronic kidney disease patients. It notes that anemia is typically normocytic and normochromic in CKD patients. The kidneys play an important role in red blood cell formation, and their dysfunction leads to anemia. The document outlines guidelines for evaluating and treating anemia in CKD patients, including ensuring adequate iron levels through supplementation and targeting a hemoglobin level of 10-11.5 g/dL through erythropoietin administration and iron therapy. Blood transfusions should be avoided when possible.
Presentation given to our fellowship program about diabetic kidney disease.
2022 update discussing SGLT2i, MRA (e.g. finerenone), health economics and beyond
Chronic kidney disease associated mineral bone disordersArshad Ali Awan
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD), which represents a systemic disorder of mineral and bone metabolism that occurs as a complication of chronic kidney disease. As kidney function declines in CKD, there are progressive changes in the serum concentrations of calcium, phosphorus, vitamins D and PTH that lead to abnormalities in bone turnover, mineralization, and structure as well as soft tissue calcification. The document outlines the pathogenesis of CKD-MBD and its skeletal complications including renal osteodystrophy, and discusses treatment goals and management strategies to address abnormal mineral metabolism and bone disease in CKD.
1. Patients with chronic kidney disease (CKD) have impaired immune responses that increase their risk of infections. Vaccinations are an important prevention strategy, though CKD patients typically have lower vaccine effectiveness compared to those with healthy kidneys.
2. Key recommended vaccinations for CKD patients include: hepatitis B vaccine (4 doses of 40 μg), influenza vaccine (annual 15 μg doses), and pneumococcal vaccine (single 0.5 mL dose). These vaccines have shown protective benefits, though antibody responses tend to be lower in CKD patients.
3. Additional strategies to improve vaccine responses include earlier vaccination as kidney function declines, intradermal administration, and booster doses for hepatitis B when antibody levels decline below
This document discusses hyperphosphataemia and its treatment in patients with chronic kidney disease. It begins by outlining the topics to be covered, including defining hyperphosphataemia, discussing calcium, phosphate, and vitamin D physiology, pathophysiological changes in CKD patients, and treatment options. It then covers the normal regulation of calcium and phosphate, how loss of kidney function disrupts this, resulting in hyperphosphataemia. Factors involved in regulating phosphate levels like PTH, vitamin D, FGF-23, and Klotho are examined. Clinical consequences of hyperphosphataemia like increased FGF-23 and vascular calcification are addressed. The document concludes by discussing clinical presentations of hyperphosphataemia.
Hyperphosphatemia in CKD patients; The Magnitude of The Problem - Prof. Alaa ...MNDU net
Hyperphosphatemia in CKD patients; The Magnitude of The Problem
Prof. Alaa Sabry - Professor of Nephrology
Mansoura Nephrology and Dialysis Unit (MNDU) Course
This document provides information on chronic kidney disease-mineral and bone disorder (CKD-MBD). It discusses the pathogenesis of CKD-MBD, classifications of bone disease seen in CKD patients, diagnostic evaluations, and treatment approaches. Key points include that CKD disrupts calcium and phosphate homeostasis, leading to secondary hyperparathyroidism and bone disease. Bone abnormalities range from high turnover disease to adynamic bone disease. Treatment focuses on controlling calcium, phosphate, PTH, and vitamin D levels to prevent complications of CKD-MBD such as cardiovascular disease.
This document discusses bone disease in chronic kidney disease. It begins with an introduction and overview of pathogenesis. It then discusses normal bone remodeling and hyperparathyroidism. It classifies bone diseases in CKD and discusses their diagnosis. Finally, it addresses treatment of bone disease in CKD, focusing on controlling calcium, phosphorus, PTH and vitamin D levels to prevent complications. The goal is to prevent mineral and bone disorder and cardiovascular disease to lower mortality rates in patients with CKD.
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It defines CKD-MBD as a systemic disorder caused by CKD that is characterized by abnormalities in mineral metabolism, bone disease, and soft tissue calcification. The document outlines the classification of CKD-MBD and renal osteodystrophy based on abnormalities in laboratory values, bone disease, and calcification. It also discusses the pathophysiology and diagnosis of renal osteodystrophy using bone biopsy and biomarkers. Imaging techniques for evaluating vascular calcification are presented along with the ongoing challenges in diagnosing and monitoring CKD-MBD.
The document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It defines CKD-MBD and explains that it involves abnormalities in calcium, phosphorus, PTH, FGF23, and vitamin D metabolism as well as bone abnormalities and extraskeletal calcification. The document then discusses the pathogenesis of CKD-MBD, including hypocalcemia, phosphate retention, decreased calcitriol activity, FGF23, secondary hyperparathyroidism, tertiary hyperparathyroidism, and skeletal resistance to PTH. It also describes bone diseases associated with CKD-MBD including osteitis fibrosa, adynamic bone disease, osteomalacia, mixed uremic osteod
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It begins with an overview of the key components involved in CKD-MBD, including calcium, phosphorus, parathyroid hormone, vitamin D, fibroblast growth factor 23, and magnesium. The document then presents two clinical cases involving patients with CKD and discusses treatment options based on their lab results. It also covers the roles of vitamin D and magnesium in vascular pathology and mortality in CKD patients. Guidelines for the treatment of secondary hyperparathyroidism from KDIGO are also summarized.
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It defines CKD-MBD and renal osteodystrophy. It notes that CKD-MBD is characterized by abnormalities in calcium, phosphorus, PTH, or vitamin D metabolism. It also discusses secondary hyperparathyroidism in CKD and characteristics of major CKD-related bone diseases. The document then presents two patient case studies and questions related to interpreting lab results and determining appropriate treatment steps for managing mineral and bone disorders in the patients.
The pathogenesis of CKD-MBD is complex, involving disruptions in mineral homeostasis and hormone levels as kidney function declines. Key factors include hyperphosphatemia, decreased calcitriol levels, and hypocalcemia. This leads to elevated PTH levels as the parathyroid glands respond to low calcium and calcitriol. Over time, the parathyroid glands become resistant due to downregulation of receptors. Progressive CKD also impairs the kidneys' ability to regulate phosphate, exacerbating hyperphosphatemia and CKD-MBD.
Mineral and Bone Disorder in Chronic Kidney Diseasedrsampadasinha
This document summarizes chronic kidney disease-mineral and bone disorder (CKD-MBD), including its definition, pathogenesis, diagnosis, and management recommendations. Specifically:
- CKD-MBD is defined as a systemic disorder involving abnormalities in calcium, phosphorus, vitamin D, PTH, and bone. It can cause skeletal and extraskeletal complications.
- As kidney function declines, abnormalities in mineral metabolism develop, leading to high or low bone turnover diseases. Phosphate retention, low calcitriol, and parathyroid gland changes drive secondary hyperparathyroidism.
- Diagnosis involves monitoring mineral levels and PTH. Bone biopsy determines the type of renal osteodystrophy
This document discusses bone and mineral disease in patients with chronic kidney disease. Key points:
1) Patients with chronic kidney disease often develop metabolic bone disease due to abnormalities in calcium, phosphorus, vitamin D, and parathyroid hormone levels. This can lead to bone abnormalities like osteitis fibrosa or adynamic bone.
2) Secondary hyperparathyroidism is common, driven by phosphorus retention, low vitamin D, and decreased calcium sensing by the parathyroid glands. High PTH then causes high bone turnover.
3) In addition to bone effects, extraskeletal calcification can occur in blood vessels, skin, and other tissues in patients with kidney disease. Care involves monitoring mineral
This document discusses anemia in chronic kidney disease (CKD). It outlines the benefits of treating anemia, including improved quality of life and reduced cardiovascular risks. It then presents a case study of a 65-year-old CKD patient with diabetes and hypothyroidism. His lab results show hemoglobin of 8.4 g/dL, ferritin of 950 ng/mL, and TSAT of 15%. The document goes on to discuss factors contributing to anemia, methods of assessing iron status, iron replacement therapies including oral and parenteral options, ESA therapies, and guidelines around hemoglobin targets in CKD patients. Safety issues of iron treatment and limitations of ESA therapy are also reviewed.
What are we missing in CKD-MBD management? - prof. Magdy El SharkawyMNDU net
This document discusses gaps in the current definitions and management of chronic kidney disease-mineral and bone disorder (CKD-MBD). It notes that while CKD-MBD is now defined more broadly than just renal osteodystrophy, clinical definitions are still lacking. Guidelines for phosphorus management need clarification on organic vs. inorganic phosphorus and dialysate calcium guidelines could be more precise. Role of magnesium and biomarkers like alkaline phosphatase are underexplored. PTH assays and their relationship to bone remodeling is also in need of better definition. Overall, this highlights several areas where CKD-MBD understanding and treatment could be improved.
Anaemia of chronic kidney disease GUIDELINES TO PRACTICE 2013Ayman Seddik
1) Anaemia is common in chronic kidney disease (CKD) due to reduced kidney function and erythropoietin production. It can cause lower quality of life and increased risk of cardiovascular complications.
2) Guidelines recommend diagnosing anaemia of CKD in adults with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 and hemoglobin ≤11 g/dL.
3) Treatment involves iron supplementation and erythropoiesis-stimulating agents (ESAs) to increase hemoglobin levels, with a target range of 11-12 g/dL according to recent guidelines. Higher targets may increase risk without clear benefits.
This document discusses anemia in chronic kidney disease patients. It notes that anemia is typically normocytic and normochromic in CKD patients. The kidneys play an important role in red blood cell formation, and their dysfunction leads to anemia. The document outlines guidelines for evaluating and treating anemia in CKD patients, including ensuring adequate iron levels through supplementation and targeting a hemoglobin level of 10-11.5 g/dL through erythropoietin administration and iron therapy. Blood transfusions should be avoided when possible.
Presentation given to our fellowship program about diabetic kidney disease.
2022 update discussing SGLT2i, MRA (e.g. finerenone), health economics and beyond
Chronic kidney disease associated mineral bone disordersArshad Ali Awan
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD), which represents a systemic disorder of mineral and bone metabolism that occurs as a complication of chronic kidney disease. As kidney function declines in CKD, there are progressive changes in the serum concentrations of calcium, phosphorus, vitamins D and PTH that lead to abnormalities in bone turnover, mineralization, and structure as well as soft tissue calcification. The document outlines the pathogenesis of CKD-MBD and its skeletal complications including renal osteodystrophy, and discusses treatment goals and management strategies to address abnormal mineral metabolism and bone disease in CKD.
1. Patients with chronic kidney disease (CKD) have impaired immune responses that increase their risk of infections. Vaccinations are an important prevention strategy, though CKD patients typically have lower vaccine effectiveness compared to those with healthy kidneys.
2. Key recommended vaccinations for CKD patients include: hepatitis B vaccine (4 doses of 40 μg), influenza vaccine (annual 15 μg doses), and pneumococcal vaccine (single 0.5 mL dose). These vaccines have shown protective benefits, though antibody responses tend to be lower in CKD patients.
3. Additional strategies to improve vaccine responses include earlier vaccination as kidney function declines, intradermal administration, and booster doses for hepatitis B when antibody levels decline below
This document discusses hyperphosphataemia and its treatment in patients with chronic kidney disease. It begins by outlining the topics to be covered, including defining hyperphosphataemia, discussing calcium, phosphate, and vitamin D physiology, pathophysiological changes in CKD patients, and treatment options. It then covers the normal regulation of calcium and phosphate, how loss of kidney function disrupts this, resulting in hyperphosphataemia. Factors involved in regulating phosphate levels like PTH, vitamin D, FGF-23, and Klotho are examined. Clinical consequences of hyperphosphataemia like increased FGF-23 and vascular calcification are addressed. The document concludes by discussing clinical presentations of hyperphosphataemia.
Hyperphosphatemia in CKD patients; The Magnitude of The Problem - Prof. Alaa ...MNDU net
Hyperphosphatemia in CKD patients; The Magnitude of The Problem
Prof. Alaa Sabry - Professor of Nephrology
Mansoura Nephrology and Dialysis Unit (MNDU) Course
This document provides information on chronic kidney disease-mineral and bone disorder (CKD-MBD). It discusses the pathogenesis of CKD-MBD, classifications of bone disease seen in CKD patients, diagnostic evaluations, and treatment approaches. Key points include that CKD disrupts calcium and phosphate homeostasis, leading to secondary hyperparathyroidism and bone disease. Bone abnormalities range from high turnover disease to adynamic bone disease. Treatment focuses on controlling calcium, phosphate, PTH, and vitamin D levels to prevent complications of CKD-MBD such as cardiovascular disease.
This document discusses bone disease in chronic kidney disease. It begins with an introduction and overview of pathogenesis. It then discusses normal bone remodeling and hyperparathyroidism. It classifies bone diseases in CKD and discusses their diagnosis. Finally, it addresses treatment of bone disease in CKD, focusing on controlling calcium, phosphorus, PTH and vitamin D levels to prevent complications. The goal is to prevent mineral and bone disorder and cardiovascular disease to lower mortality rates in patients with CKD.
This document provides information on bone disease in chronic kidney disease (CKD). It discusses the pathogenesis of bone disease in CKD, which is caused by disrupted calcium and phosphate homeostasis as kidney function declines. This leads to secondary hyperparathyroidism as phosphate levels rise and calcitriol production decreases. The document describes different classifications of bone disease in CKD including high turnover disease and adynamic bone disease. Diagnosis involves monitoring levels of PTH, calcium, and phosphate from blood tests. Treatment aims to control these mineral levels as well as vitamin D to prevent complications of CKD-mineral and bone disorder like cardiovascular disease.
This document discusses chronic kidney disease-mineral and bone disorder (CKD-MBD). It provides stages of CKD based on glomerular filtration rate. It also discusses abnormalities in mineral metabolism that occur in later CKD stages including elevated PTH, phosphorus, and decreased calcium and vitamin D. The document outlines classifications of bone disease in CKD including osteitis fibrosa, adynamic bone disease, and amyloidosis. It discusses treatments for abnormal mineral metabolism including phosphate binders and vitamin D analogs to control calcium, phosphorus, and PTH levels.
Dr. Ahmed Mohamed Albeyaly is a nephrology specialist and moderator in Dakahlia Health directorate. He specializes in treating bone disease in patients with chronic kidney disease. Bone disease in CKD is caused by abnormalities in calcium, phosphorus, PTH, and vitamin D metabolism which disrupt bone remodeling. It is classified based on bone turnover and the presence of soft tissue calcification. Diagnosis involves monitoring laboratory values of calcium, phosphorus and PTH over time alongside imaging studies. Treatment focuses on controlling these mineral and hormone levels through diet, phosphate binders, vitamin D analogues and parathyroidectomy to prevent further bone disease and cardiovascular complications.
Disease related mineral and bone disorderOther Mother
1. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is a systemic disorder affecting mineral and bone metabolism in patients with CKD.
2. Proper classification and definitions of CKD-MBD and its related conditions like renal osteodystrophy are needed to improve diagnosis and treatment.
3. Abnormalities in mineral metabolism like high phosphorus and PTH levels are linked to increased mortality in patients with CKD, so controlling these factors is important for improving outcomes.
This document summarizes the concept of chronic kidney disease-mineral and bone disorder (CKD-MBD). It defines CKD-MBD as a systemic disorder due to abnormalities in calcium, phosphorus, PTH, or vitamin D metabolism, as well as abnormalities in bone health and soft tissue calcification. The document then discusses key aspects of CKD-MBD pathogenesis including the roles of phosphorus retention, PTH, FGF23, and vitamin D. It highlights the importance of controlling phosphorus levels even in early CKD to prevent downstream effects on bone and mineral metabolism.
This document discusses osteoporosis treatment in patients with chronic kidney disease (CKD). It notes that while CKD patients have a high risk of fracture similar to postmenopausal osteoporosis, CKD-mineral and bone disorder (CKD-MBD) is more complex. Evaluating fracture risk in CKD patients is challenging as laboratory tests, bone turnover markers, and imaging modalities all have limitations. Bone biopsy remains the gold standard but has limitations for use in clinical practice. Treatment should be based on the underlying pathophysiology and more research is needed on fracture outcomes in CKD-MBD patients.
This document discusses a case of uremic leontiasis ossea in a 62-year-old male with chronic kidney disease and secondary hyperparathyroidism. He presented with severe bone deformities and high parathyroid hormone levels. Tests found hyperplasia of the parathyroid glands. He underwent parathyroidectomy with removal of five glands, one being supernumerary. Post-operatively, his calcium, phosphorus, and parathyroid hormone levels improved significantly. The case demonstrates how prolonged secondary hyperparathyroidism can lead to severe bone deformities but can be treated with surgery.
This case report describes a patient with severe uremic leontiasis ossea (ULO), or "lion face syndrome", due to longstanding uncontrolled secondary and tertiary hyperparathyroidism from end-stage renal disease. Over many years, the patient's hyperparathyroidism progressed due to non-compliance with treatment, resulting in extensive bone deformities, fractures, and disfigurement of the facial bones. Imaging showed thickening and enlargement of the maxilla and mandible bones, giving her face a lion-like appearance. The report discusses the pathophysiology of hyperparathyroidism in kidney disease and reviews the management challenges posed by this rare but preventable complication.
CKD MBD & osteoporosis in elderly the management dilemmaAyman Seddik
1. The document discusses the management of chronic kidney disease-mineral bone disease (CKD-MBD) and osteoporosis in elderly patients, highlighting the diagnostic challenges and treatment considerations.
2. It presents the case of a 54-year-old woman with end-stage renal disease and a hip fracture, exploring the differential diagnosis of CKD-MBD versus osteoporosis based on her history and lab results.
3. The management of bone disease in CKD patients requires careful exclusion of other forms of renal bone disease through biomarkers or bone biopsy to determine if osteoporosis treatments may be appropriate.
8-2. Management of chronic renal failure. Isidro Salusky (eng)KidneyOrgRu
This document summarizes research on chronic kidney disease in children. It includes:
1) Mortality rates are much higher for children on dialysis compared to the general pediatric population, especially for certain demographic groups.
2) Common causes of chronic kidney disease in children include congenital abnormalities, genetic disorders, and diabetes.
3) Growth failure is a major complication and is associated with protein and calorie malnutrition as well as metabolic bone disease.
4) Treatment involves optimizing nutrition, managing acidosis and mineral disorders, and considering growth hormone therapy.
This document outlines learning objectives and content for a lecture on chronic kidney disease (CKD). The objectives include differentiating CKD from acute kidney injury, describing CKD progression and therapies, comparing CKD causes and risk factors, and classifying CKD stages. The content covers normal kidney function, definitions of CKD and end-stage renal disease, CKD etiologies and risk factors, CKD stages, pathophysiology, complications involving mineral bone disorders, cardiovascular issues, and management strategies including nutrition, electrolytes, anemia, and medications.
Renal disorders can cause complications like chronic kidney disease (CKD) that increase risks during dental procedures and surgery. Patients with CKD are more likely to experience bleeding due to platelet and blood vessel dysfunction, and also have increased risk of infection. They may also develop dental problems such as periodontal disease, tooth discoloration and loss of enamel. When undergoing surgery, CKD patients are at higher risk of complications including bleeding, infections, cardiovascular and thrombotic events due to changes in fluid, electrolyte and acid-base balance as well as altered drug metabolism and clearance. Careful preoperative evaluation and management involving nephrologists can help reduce these perioperative risks.
The document discusses renal osteodystrophy, which refers to bone diseases that occur in patients with impaired kidney function. It outlines several types of renal osteodystrophy, including osteitis fibrosa, adynamic bone disease, and osteomalacia. It describes the pathogenesis of secondary hyperparathyroidism in kidney disease and the effects of parathyroid hormone and vitamin D on bone and mineral metabolism. Treatment goals are to control parathyroid hormone levels, calcium, phosphorus, and vitamin D to prevent bone complications in renal patients.
This document discusses the physiology and clinical management of PTH and mineral metabolism disorders in patients with chronic kidney disease (CKD). It provides an overview of calcium, phosphorus, vitamin D, and PTH regulation and how their homeostasis is disrupted in CKD. Secondary hyperparathyroidism leads to elevated PTH levels and disturbances in calcium and phosphorus. If not properly managed, this can result in renal osteodystrophy, vascular calcification, and increased risk of cardiovascular events and mortality. The document reviews therapeutic options like phosphate binders and vitamin D analogs to control mineral levels and treat secondary hyperparathyroidism in CKD patients.
Calcification of coronary arteries is highly prevalent among chronic kidney disease (CKD) patient populations according to three studies. The percentage of CKD patients with coronary artery calcification across the studies ranged from 51% in CKD patients not on dialysis to 83% in prevalent dialysis patients. Vascular calcification is associated with increased cardiovascular risk and mortality. Non-invasive imaging such as lateral abdominal x-rays and echocardiograms can detect the presence of vascular and valvular calcification, identifying patients at highest risk. One study in Thailand found the overall prevalence of abdominal aorta calcification among CKD patients was 70.7%, with similar rates between those not on dialysis and those undergoing dialysis.
This document discusses the management of bone disease in patients with cystinosis. It notes that patients experience rickets and renal osteodystrophy due to the metabolic consequences of Fanconi syndrome and chronic kidney disease. The pathogenesis involves defects in osteoblasts and mineralization, as well as hormonal imbalances. Treatment involves replacing urinary losses, optimizing nutrition, and administering phosphate, calcium, vitamin D, and growth hormone as needed based on lab values and growth parameters. Surgery may be used to treat bone deformities, and nephrectomy could help in some cases on renal replacement therapy.
Bone physiology, OSTEOPOROSIS, Pagets Disease, HyperparathyoidismKaushal Kafle
A brief introduction to bone physiology, with more focus on Osteoporosis and its recent updates. Small tail topics include hyperparathyroidism and pagets disease.
Introduction to Chronic Kidney Disease epidemiology, diagnosis, treatment of complications and system issues (e.g. interface between nephrology and primary care, specialty referrals) for medical students
The document provides historical background on the development of peritoneal dialysis (PD) and outlines its use in acute kidney injury (AKI). It discusses:
1. The first experiments using the peritoneal cavity for uremia removal in the 1920s.
2. The development of intermittent PD in the 1960s and continuous ambulatory PD in the 1970s.
3. Evidence that high doses of continuous PD can provide appropriate metabolic control in AKI, with survival and renal recovery rates similar to other renal replacement therapies.
4. Indications for acute PD include hemodynamic instability and bleeding risks, while contraindications include recent abdominal surgery and severe peritonitis.
This document summarizes a presentation on therapeutic plasma exchange (PEX) given by Kamal Mohamed Okasha. It provides an overview of the PEX procedure and potential indications for PEX, including Goodpasture's Syndrome, thrombotic thrombocytopenic purpura, cryoglobulinemia, multiple myeloma, and ANCA disease. It discusses complications of PEX and guidelines for efficacy based on recent studies. In particular, it examines the use of PEX for Goodpasture's Syndrome, noting that PEX aims to remove circulating anti-GBM antibodies and that studies have found improved outcomes, including renal function and survival, for patients receiving PEX treatment.
Hussein drug therapy in aki 3 osama alshahat 2 pptxFarragBahbah
This document discusses acute kidney injury (AKI). It notes that AKI is often not recognized or coded for correctly. The incidence of AKI is increasing globally due to factors like comorbidities. Treatment for AKI is mainly supportive as there are no effective preventative or curative treatments. Several studies discussed found that diuretics and mannitol did not prevent AKI and may increase the risk of contrast-induced nephropathy. Hydration with sodium bicarbonate or saline was compared, with meta-analyses finding sodium bicarbonate may reduce the risk of AKI compared to saline. Dopamine and fenoldopam were also discussed but did not show clear benefits for preventing or treating AK
This document summarizes key information about lupus nephritis (LN) from a lecture given by Dr. Hussein Sheashaa. It begins with an outline of topics to be covered, including histopathology/biopsy, predictors of outcome, treatment approaches, and special situations. Regarding biopsy findings, it indicates that class IV LN is most common and describes revised classification guidelines. Treatment principles focus on early, aggressive therapy to achieve remission and prevent flares/progression. Standard induction therapies are discussed as well as new options like voclosporin. Maintenance strategies and treatment algorithms are presented. Predictors of poor outcome and management of special cases like pregnancy and refractory LN are also summarized.
This document summarizes key aspects of fluid management in peritoneal dialysis (PD) patients. It discusses optimizing PD prescriptions to balance adequate solute clearance while avoiding excess dialysis fluid exposure. Factors like residual renal function, membrane characteristics, fill volume and dwell time are considered. Monitoring adequacy includes measuring clearances and adjusting therapy if targets are not met. Guidelines recommend strategies to preserve renal function like ACEi/ARB use and avoiding dehydration.
Membranous nephropathy 22 october 2019, prof. hussein sheashaaFarragBahbah
This document summarizes a presentation on membranous nephropathy (MN). The presentation discusses: 1) The pathogenesis and pathology of MN, focusing on its autoimmune nature. 2) Immunosuppression treatments for MN including calcineurin inhibitors (CNIs), rituximab, and newer therapies. 3) Algorithms and guidelines for the management and treatment of MN. 4) Recent 2019 clinical studies on treatments like rituximab and CNIs. 5) Recurrent MN after kidney transplantation. 6) The use of circulating anti-PLA2R antibody levels to diagnose and monitor MN noninvasively.
This document discusses different modalities for treating acute kidney injury (AKI) in critically ill patients, including continuous renal replacement therapy (CRRT) and intermittent hemodialysis. It provides pros and cons of each modality and factors to consider in determining the optimal treatment for an individual patient. While CRRT allows for more gradual fluid removal and hemodynamic stability, clearance is better with intermittent therapies. The document concludes that hemodynamic stability is the main determinant of treatment choice and clearance is optimized through combination of diffusion and convection methods.
This document provides an outline and summary of a presentation on diabetic kidney disease (DKD). It discusses:
1. The epidemiology, presentation, and trends of DKD.
2. The pathology and biomarkers of DKD.
3. The management of DKD, including the use of RAAS blockers, anti-hyperglycemic drugs like SGLT2 inhibitors and GLP1 RAs, and renal replacement therapies.
4. It concludes with a discussion of taking a holistic approach to DKD and lessons that can be learned from basic research on autophagy.
The document discusses several cases of glomerular disease:
1) A 27-year-old male with nephrotic syndrome and a kidney biopsy showing IgG and C3 deposits along the glomerular basement membrane consistent with membranous nephropathy.
2) A 78-year-old female admitted with nephrotic syndrome after a history of NSAID use, with a biopsy showing focal segmental glomerulosclerosis.
3) A 26-year-old male with nephrotic syndrome and renal impairment, whose biopsy demonstrated membranoproliferative glomerulonephritis with C3 deposition and subendothelial electron dense deposits. Follow up showed elevated
A 30-year-old man presented with lower limb swelling, shortness of breath, and decreased urine output for 2 weeks. He had a history of drug abuse including heroin, tramadol, and marijuana. Initial labs showed severe kidney dysfunction with a creatinine of 7.5 mg/dl. A renal biopsy was performed which showed acute tubular injury, focal interstitial nephritis with eosinophil infiltrate, and mesangial proliferative glomerulonephritis. He was started on hemodialysis and steroids. After treatment, his kidney function improved and he was discharged with a creatinine of 1.5 mg/dl.
A 19-year-old male gym player presented with decreased urine output, fatigue, loss of appetite, joint pain, nausea, and vomiting for one week. Lab results showed impaired renal function. He has a history of artheralgia treated with long-acting penicillin. Investigations showed positive ANA and anti-ds DNA. A renal biopsy was done which revealed lupus nephritis class 4, indicating an active inflammation. The treatment plan includes high dose steroids, immunosuppressants, and supplements.
This document discusses tubulointerstitial nephritis (TIN), a pattern of renal injury characterized by inflammation and edema of the renal tubules and interstitium. TIN is most commonly caused by drugs (71% of cases) and infections (15% of cases). On biopsy, TIN shows lymphocytic infiltration of the tubules and interstitium with tubular atrophy and normal glomeruli and vessels. Treatment involves withdrawing the offending agent and supportive care. Corticosteroids may aid recovery but their effectiveness is debated. Prognosis depends on factors like duration of the insult and degree of fibrosis - complete recovery is more likely if treatment begins early.
Fasting ramadan nephrology prospective prof. osama el shahateFarragBahbah
Dr. Osama El-Shahat is the head of the nephrology department at New Mansoura General Hospital and vice president of the Dakahlia Nephrology Group. The document discusses kidney disease (CKD), transplantation, dialysis, and recommendations. It provides examples of how some animals fast during certain periods by not eating and reducing activity. It also discusses fasting guidelines for patients with illnesses, noting that those with more severe illnesses should generally be exempted from fasting. The document analyzes a study on the effects of Ramadan fasting on renal function in CKD patients and notes that more large studies are needed. It also reviews a case of a hypertensive patient wanting to fast for Ramadan
Ramadan fasting & kidney disease may 2019FarragBahbah
Ramadan fasting is a unique metabolic model that consists of alternating periods of fasting and feasting rather than continuous fasting. During the fast, the body breaks down fat stores and releases fatty acids into the bloodstream to be used for energy. This process can help eliminate toxins from the fatty acids. Fasting has also been shown to help reduce inflammation and support the immune system. However, fasting also carries risks and may not be appropriate for certain groups like pregnant women, those with medical conditions, or people on medication. Proper hydration and electrolyte replacement is important when fasting to avoid health issues.
- Short-term catheters should only be used for acute dialysis or limited hospital use. Non-cuffed femoral catheters are only for bed-bound patients.
- Long-term catheters should be used with a plan for permanent access and prefer those capable of high flow rates. Choice depends on local experience and goals.
- Long-term catheters should avoid the same side as a maturing arteriovenous access, if possible.
This document summarizes the medical history and treatment of a 55-year-old male patient with end-stage renal disease on hemodialysis for 17 years and secondary hyperparathyroidism. Medical treatment with cinacalcet and calcitriol was unsuccessful in lowering his high calcium, phosphorus, and PTH levels. Consultations with ENT and cardiology found no issues. The doctor decided that parathyroidectomy was the best option to treat his tertiary hyperparathyroidism that was not responding to medical treatment.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfRahul Sen
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
4. Evolutionof CKD-MBD
Bone changes in renal failure patients, mainly
hyperparathyroidism, begin early in the natural history of
the disease.
About 50% of the patients have histological evidences of
bone disease when GFR is halved.
Almost all patients with CRF on regular heamodialysis
has evidance of ROD
5. Renal Bone Disease
This disorder is often subclinical, and its
presence is suggested from abnormal laboratory
tests such as;
hyperphosphatemia, high circulatory levels of
PTH, and low levels of 1,25(OH)2D3.
In other patients, however, renal osteodystrophy is
a cause of great morbidity.
6. Population Attributable Risk of All
Cause Mortality in CKD 5D
• 17.5% Mineral metabolism abnormalities
(Phosphorus > 5.0 mg/dl, Calcium > 10 %
mg/dl, intact PTH > 600 pg/ml)
• 11.3% Anemia (hgb < 11 g/dl)
• 5.1% Inefficient Dialysis (URR < 65%)
Corollary: We should be able to significantly improve
mortality of CKD patients by improving control of
mineral metabolism
•Block et al JASN 2004Block et al JASN 2004
7. Akmal M et al. Kidney Int. 1995;47:158-163.
Drüeke TB. Nephrol Dial Transplant. 1996;11(suppl 3):37-42.
Hsu CH. Am J Kidney Dis. 1997;29:641-649. .
Soft-Tissue Calcification
Type of Calcification Morbid Effects
Myocardiam and valves Atrioventricular block, cardiac failure,
pulmonary hypertension, arrhythmia, left and
right ventricular hypertrophy, sudden death
Peripheral arteries Bone and soft tissue necrosis, amputation
Skin arterioles Calcific uremic arteriolopathy (calciphylaxis)
Pulmonary Cough, dyspnea, restrictive defects,
decreased diffusion, hypoxia
8. *P=0.01 vs Ca × P product 43-52 mg2
/dL2
.
Block GA et al. Am J Kidney Dis. 1998;31:607-617.
The Importance of Ca × P Product:
A Key Determinant of Mortality Risk
1.06
1.00
1.08
1.13
1.34*
1.00
1.25
1.50
1.1-3.4 40-45 50-55 56-65 66-780
RelativeMortalityRisk(RR)
n=2669
Ca × P Product Quintile (mg2
/L2
)
9. *P=0.03 vs phosphorus 4.6-5.5 mg/dL.
†
P<0.0001 vs phosphorus 4.6-5.5 mg/dL.
Block GA et al. Am J Kidney Dis. 1998;31:607-617.
Elevated Serum Phosphorus Increases
Mortality Risk
1.00
1.25
1.50
0.40-1.45 1.46-1.80 1.81-2.10 2.11-2.55 2.56-5.50
RelativeMortalityRisk(RR)
Serum Phosphorus Quintile (mmol/L)
1.00 1.00
1.02
1.18*
1.39†N=6407
10. Coronary-artery calcificationsCoronary-artery calcifications
increase with years of dialysisincrease with years of dialysis
1.0
0
Years of dialysis
Proportionwith
calcification
0.8
0.6
0.4
0.2
0.0
4 8 12 16 20 24
Patients with coronary-
artery calcification (n = 39)
Estimates by logistic
regression analysis
Goodman WG et al. N Engl J Med 2000;342:1478–83.
11. Definition, Evaluation and Classification
of Renal Osteodystrophy:
ApositionstatementfromKidneyDisease
ImprovingGlobalOutcomes (KDIGO)
April, 2006
13. Definition of CKD-MBD
A systemic disorder of mineral and bone
metabolism due to CKD manifested by
either one or a combination of the
following:
– Abnormalities of calcium, phosphorus, PTH, or
vitamin D metabolism
– Abnormalities in bone turnover, mineralization,
volume, linear growth, or strength
– Vascular or other soft tissue calcification
• Moe et al Kidney International June 2006
14. Standardization of Terms
• The term renal osteodystrophy (ROD) should
be used exclusively to define the bone
pathology associated with CKD.
• The clinical, biochemical, and imaging
abnormalities should be defined more broadly
as a clinical entity or syndrome called Chronic
Kidney Disease-Mineral and Bone Disorder
(CKD-MBD).
15. A Framework for Classification of CKD-MBD
Type*
Laboratory
Abnormalities
Bone Disease
Calcification of
Vascular or Other
Soft Tissue
L + - -
LB + + -
LC + - +
LBC + + +
* L = laboratory abnormalities (of calcium, phosphorus, PTH,
alkaline phosphatase or vitamin D metabolism); B = bone disease
(abnormalities in bone turnover, mineralization, volume, linear
growth, or strength); C = calcification of vascular or other soft
tissue.
•KidneyInternationalJune2006
16. KI (2007) 71, 31-38. Levin et. al.
Prevalence of Abnormal Mineral Metabolism in CKD
•>4.6
17.
18.
19.
20. The factors involved in the pathogenesis of secondary hyperparathyroidism.
Kevin J. Martin, and Esther A. González JASN 2007;18:875-885
25. Consequences of HyperphosphatemiaConsequences of Hyperphosphatemia
P
Mortality
Risk of
Calcification
Parathyroid
Cell Growth
PTH Secretion
PTH Resistance
Ca++
Calcitriol Resistance
Calcitriol
26. VDR = vitamin D receptor; CaR = Ca-Sensing receptor.
Adapted from Murayama A et al. Endocrinology. 1999;140:2224-2231. Satomura K et al. Kidney Int. 1988;34:712–716
CKD ProgressionCKD Progression
Normal Diffuse Early
nodular
Nodular
hyperplasia
Single nodule
Monoclonal nodules
Decline in
receptor density
of VDR, CaR
Cells with lower density of VDR
proliferate vigorously to form
several monoclonal nodules
Progression of PTH Gland Hyperplasia
in CKD
27.
28. Increased FGF23 develops earlier than
increased phosphate or PTH
Isakova T et al., Kidney Int 2011
29.
30. Pathogenesis of Different Types of ROD
There are five components in the pathogenesis of renal
osteodystrophy:
1- Secondary hyperparathyroidism (HTO) due to:
-Phosphate retention. - An abnormal set point for calcium.
- Altered metabolism of vit.D. - Skeletal resistance to PTH.
- Impaired degradation of PTH.
- Altered feed back regulation of PTH by calcium.
2- Adynamic bone disease: (Defective meniralization of bone (LTO)
- Altered vitamin D metabolism. - Acidosis.
- Altered synthesis and maturation of collagen.
- Retention of aluminum. - Retention of iron.
- Skeletal accumulation of magnesium, fluoride,pyrophosphate, and
oxalately stranchium..
3- MUD.
4 - Osteosclerosis.
5- -Osteoporosis .
31.
32. Clinical Manifestations of Renal
Osteodystrophy
The symptoms of renal osteodystrophy usually
appear when renal failure is advanced and
thus appear in dialysis patients, except in some
etiologies of renal failure when there is
prolonged course of disease before the need of
dialysis, as in
– analgesic induced renal disease, or
– when the patient present late in-spite of advanced
renal failure
– Renal transplant patients.
34. Bone Pains
Causes are: osteitis fibrosa cystica,
osteomalacia, osteoarthritis, β2-
microglobulin amyloidosis.
Fibromyalgia induces more diffuse
muscle and soft tissue pain.
Radiography may reveal
pseudofractures of the pelvis, femurs,
metatarsals, or lateral margins of the
scapulae.
Therapy of chronic pain has to be
adapted to the individual patient with
special regard to the presence of a high
or low bone turnover osteopathy.
36. UREMIC MYOPATHY
MUSCLE WEEKNESS
The development of a myopathy in CKD causes
proximal muscle weakness and wasting, predominantly
in the muscles of the lower limbs.
Uremic myopathy typically develops with glomerular
filtration rates of <25 ml/min, and has been associated
with fatigability and reduced exercise capacity.
Electromyography and creatine kinase levels are
generally normal, and the diagnosis is, therefore, made
largely on clinical grounds.
Campistol,. Kidney Int. 62, 1901-1913 (2002).
38. Bone Fractures
Worldwide, one in three women and one in five
men over the age of 50 will have a fracture
This is very different from what is known in men
and women with chronic kidney disease (CKD).
Data from a large cohort of patients of (NHANES
III) in USA demonstrate that compared with those
with (eGFR) of greater than or equal to 60 ml/min,
those with an eGFR less than 60 ml/min had a
twofold increased risk of hip fractures.
39. Bone Fractures
On the other hand, the prevalence
of vertebral fractures in CKD
patients is similar to that in the
general population.
– Fusaro et al., Calcif Tissue Int 2013
There are data indicating that impaired
neuromuscular function, probably
resulting in increased incidence
of falls, is assciated with fractures in
patients with CKD.
– Barreto, Kidney Int 2008
40. Yearly incidence of hip fracture
Reference Country HD General population with simil
USA 1% 0.22%
2012 DOPPS 2 countries 0.89% 0.47–1.57% 0.07–0.22%*
↵*References available in [2].
Michel Jadoul, NDT, 2012
41. Pseudogout
Calcium pyrophosphate dihydrate deposition disease is a crystal
arthritis, crystal deposition in the articular cartilage or synovium.
In chronic kidney disease patients, the major causes of crystal
arthritis are calcium oxalate crystals and basic calcium
phosphate crystals.
Although considered uncommon, pseudogout may cause acute
arthritis in chronic renal failure more often than previously
suspected.
Joint aspiration and identification of CPPD crystals with
compensated polarized light microscopy will establish the diagnosis of
pseudogout.
– Michael et al., Arch Intern Med .1979.
42. Tendon Rupture
• Spontaneous tendon
rupture is a rare complication
which severely disables
patient's activity.
• It generally occurs in
association with different
chronic metabolic disorders,
chronic renal failure, gout and
obesity.
• Especially rare are
simultaneous, spontaneous,
(the quadriceps femoris,
Achilles and patellar tendon).
• Nikolina KIDNEY AND BLOOD PRESSURE RESEARCH ·
2009
43. Pruritus
A terrible symptom that may be related to
PTH
Persistent uremic pruritus of patients with
secondary hyperparathyroidism decreased
after parathyroidectomy
Intradermal application of parathormone did
not cause a significant skin reaction in
humans.
Itching can occur in patients with accepted
PTH serum level.
Kleeman CR et al. Trans Assoc Am Physicians. 1968;81:203–212.
Massry SG et al. N Engl J Med. 1968;279(13):697–700.
Ståhle-Bäckdahl M et al. J Intern Med. 1989;225(6):411–415.
7
46. Extra-skeletal manifestations
It is a systemic disorder affecting soft tissues, particularly
vessels, heart valves and skin.
Coronary artery and vascular calcifications occur
frequently in CKD 5 (and increase each year on dialysis)
CVD accounts for around half
of all deaths of dialysis patients.
47. “If we X-Ray most of our patients, they’ve got “tram tracks” – we hardly
need an angiogram!”
48. Types of calcification
1. Focal calcification associated
with lipid laden atherosclerotic plaques
• Increases fragility and risk of plaque rupture
1. Diffuse calcification
• not in atherosclerotic plaques and occurs in media of vessels
• Called “Monckeberg’s sclerosis”
• Increases blood vessel stiffness and reduces vascular
compliance
Results in widened pulse pressure
Increased afterload
LVH
• Contributing to CVD morbidity
49.
50.
51.
52. Extra-skeletal manifestations
• Important to recognize
disordered bone and mineral
metabolism is a systemic
disorder affecting soft tissues,
particularly vessels, heart
valves and skin.
• CVD accounts for around half
of all deaths of dialysis
patients.
• Coronary artery and vascular
calcifications occur frequently
in CKD 5 (and increase each
year on dialysis)
53. Calciphylaxis or calcemic uremic arteriolopathy (CUA)
–Seen primarily in CKD 5
–Occurs in 1-4% of dialysis
patients
–Presents with extensive
calcification of the skin,
muscles and SC tissues.
Extensive medial calcification of
small arteries, arterioles, capillaries
and venules.
Clinically they may have skin
nodules, skin firmness, eschars,
livedo reticularis and painful
hyperaesthesia of the skin.
May lead to non healing ulcers and
gangrene
Brandenburg et al., Journal of nephrology 2011
54. Calciphylaxis
• A, Confluent calf plaques (borders
shown with arrows).
Parts of the skin are erythematous,
which is easily confused with simple
cellulitis.
• B, Gross ulceration in the same patient
3 months later. The black escharhas
been surgically débrided.
• C, Calciphylactic plaques, a few of
which are beginning to ulcerate.
• (Photographs courtesy of Dr. Adrian Fine. Up To
Date)
55. Angulated black eschar with surrounding livedo.
Note the bullous change at the inferior edge of the eschar.
56. Amyloidosis
Pts on dialysis for 7- 10 years can develop osteoarticular amyloid
deposits.
May present with carpel tunnel syndrome and arthritis
58. Management of ROD
• Detection of the type of ROD
• Define goals of therapy
• Follow the guidelines (KDOQI)
• Prevent ROD in predialysis patient
(CKD III, IV)
59. Management of ROD
• Diagnosis of ROD
• Biochemical Markers
• Radiology
• Histology and Pathology
61. X-Ray studies:
Traditional X-ray cannot help in defining the existent
histologic pattern of osteodystrophy and the rate of bone
turnover.
Bone densitometric studies:
It is probably safe to state that densitometric techniques
in renal disease are mainly useful in the follow up control
of renal bone diseases.
62. Radiographic signs in hand skeletons of haemodialysis
patients with severe secondary hyperparathyroidism
•)b) periostal new bone formation
)periostal neostosis) )arrow);
• )c) subperiostal resorption zones )arrow).
• Both )b) and )c) show cortical thinning, cortical striation, and fluffy trabecular
structure.
63. Resorptive defects of diploë (pepper-pot aspect) in the skull of a
haemodialysis patient with severe hyperparathyroidism.
64. Increased density of ground plates of vertebrae contrasting with
radiolucency of the central vertebral slices (rugger jersey spine) in a
haemodialysis patient with severe hyperparathyroidism. Note the severe
aortic calcification.
65. Bone Biopsy and Histomorphometry
Bone biopsy can be taken either by needle
and is satisfactory for clinical purposes, or by
using electrical drill.
Bone dynamic studies:
The administration of tetracycline, that
localizes at the mineralizing surface and
whose fluorescence can be detected by
ultraviolet microscopy, is able to provide
dynamic information’s about bone turnover.
66.
67. Therapeutic Modalities of Renal
Osteodystrophy:
•I-Control of calcium:
•Calcium supplementation.
•Vitamin D analogues.
•Choice of dialysate calcium
concentration.
•II-Control of phosphorus:
•Dietary phosphate restriction.
•Removal of phosphorus by
dialysis
•Phosphate-binding.
68. •III-Control of Parathyroid glands:
•Control of phosphorus
•Control of calcium
•Vit D Analogues
•Calcimimetics
•Parathyroidectomy.
•V-Removal of aluminum: disferrioxamine.
69. The new vitamin D analogues
Paricalcitol (Zemplar), or 19-nor-1alpha,25-
dihydroxyvitamin D2. .
• It binds specifically with vitamin D receptors on the
parathyroid gland, where it suppress the secretion of
PTH by about 60%,,and at the same time it does not
increase the intestinal absorption of calcium or
phosphorus.
Paricalcitol results in 10 times less elevation of serum
calcium than calcitriol It is 10 times less effective in
mobilising calcium and phosphorus from bone side
effect includes: fever, chills, feeling unwell.
Block GA. Clin Nephrol. 2000;54:318-324.
70. The new vitamin D analogues
Doxercalciferol (Hectorol), is a synthetic vitamin D2
undergoes metabolic activation in vivo to form 1a,25-
dihydroxyvitamin D2 (1a,25-(OH)2D2)
• Doxercalciferol is absorbed from the gastrointestinal
tract and activated by CYP 27 in the liver to form 1 ,25-
(OH)2D2 (major metabolite) and 1 ,24-
dihydroxyvitamin D2 (minor metabolite)..
• Precautions in:
• liver disease
• Pregnancy
• breast-feeding
Block GA. Clin Nephrol. 2000;54:318-324.
71. Summary
Calcium
In hypocalcemic patients
Calcium supplement
Calcium
Calcium containing PO
binders
In hyercalcemic patients
Calcium restrictions
Avoid Calcium Containing
PO binders
Dialysate calcium
Phosphorus
• Dietary Phosphate
Restriction
• Dialysis
• Phosphate Binding
Agents
• Ca containing
• Non Ca
Containing
• Metal based
• Ferric citrate
Parathyroid Gland
• Phosphorus
• Calcium
• Vitamin D analogues
• Parathyroidectomy
• Local Parathyroid gland
injection
• Alcohol
• Vitamin D
• Calcimimetics
72. Recommendations
• Aim for long-term serum phosphorus 3.0-
5.5 mg/dL
• Aim for long-term Ca × P product of <55
mg2
/dL2
• Monitor PTH level.
• Monitor calcium intake.
• Avoid agents that accumulate and cause
metal toxicity (aluminum)
• Avoid unneeded use of Vit. D analogues
Block GA. Clin Nephrol. 2000;54:318-324.
Llach F. Am J Kidney Dis. 1998;32:514-518.
Editor's Notes
Key Point: Soft-tissue calcification can affect many tissues, including the heart, peripheral blood vessels, and lungs. Deposition of calcium in these tissues can result in a wide range of adverse events.
Depending on the location and severity of calcification, patients may experience a range of morbid effects, some of which can be severe and potentially life threatening. Myocardial and valvular calcification have the potential to result in atrioventricular block, cardiac failure, pulmonary hypertension, arrhythmia, and left and right ventricular hypertrophy. Calcification of peripheral arteries may result in bone and soft tissue necrosis and requirement for amputation. Calcification of skin arterioles may result in calcific uremic arteriolopathy. Pulmonary deposition of calcium may lead to cough, dyspnea, restrictive defects, decreased diffusion, and hypoxia. [Drüeke, 1996, 37A,B, 38A, 40A; Rostand, 1988, 651A-C; Akmal, 1995, 158A,B, 160A; Hsu, 1997, 645A; Janigan, 2000, 588A]
Akmal M, Barndt RR, Ansari AN, Mohler JG, Massry SG. Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int. 1995;47:158-163.
Drüeke TB. A clinical approach to the uraemic patient with extraskeletal calcifications. Nephrol Dial Transplant. 1996;11(suppl 3):37-42.
Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis. 1997;29:641-649.
Janigan DT, Hirsch DJ, Klassen GA, MacDonald AS. Calcified subcutaneous arterioles with infarcts of the subcutis and skin (&quot;calciphylaxis&quot;) in chronic renal failure. Am J Kidney Dis. 2000;35:588-597.
Rostand SG, Sanders C, Kirk KA, Rutsky EA, Fraser RG. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med. 1988;85:651-657.
Key Point: Elevated Ca P product is associated with increased mortality risk in stage 5 CKD patients.
Block and colleagues demonstrated that an elevated calcium-phosphorus product (Ca P) was associated with increased risk of death in patients included in Case Mix Adequacy Study (CMAS) and Dialysis Morbidity and Mortality Study (DMMS) Wave 1. Serum phosphorus analysis was based on combined data from CMAS and DMMS (N=6407), while the Ca P analysis was derived from DMMS (n=2669) alone (CMAS did not include Ca P data). Patients with Ca P product &gt;5.8 mmol2/L2 had a 34% higher risk of death relative to patients with a Ca P product in the reference range (3.5-4.2 mmol2/L2, P&lt;0.01). This Ca P reference range was chosen based on published findings that cited it as desirable in the stage 5 chronic kidney disease (CKD) population. [Block, 1998, 610A, 612B, 613A,B]
Block GA, Hulbert-Shearon TE, Levin NE, Port FK. Association of serum phosphorus and calcium phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
Key Point: Risk for mortality in dialysis patients rises with increased serum phosphorus levels.
The clinical significance of poor phosphorus management is well illustrated by results reported by Block and colleagues. [Block, 1998, 607A,B] Retrospective analysis of data from 6407 hemodialysis patients revealed that elevated serum phosphorus levels are associated with increased risk for death. Relative mortality risk by quintiles remained flat when serum phosphorus was &lt;2.1 mmol/L and increased markedly when phosphorus was above this level. Using 2.1, 1.9, and 1.6 mmol/L as cut-off levels for poor phosphorus control, it was shown that patients with phosphorus levels &gt;2.1 mmol/L had a relative mortality risk of 1.27 (P&lt;0.001), patients with phosphorus levels &gt;1.9 mmol/L had a relative mortality risk of 1.19 (P=NS), and patients with phosphorus levels &gt;1.6 mmol/L had a relative mortality risk of 1.11 (P=NS). After adjusting for age at stage 5 chronic kidney disease (CKD) onset, race, sex, diabetes, acquired immunodeficiency syndrome (AIDS), neoplasm, and active smoking, patients with phosphorus levels &gt;2.1 mmol/L had a 27% higher risk of death than patients with phosphorus levels in the range of 0.8 mmol/L to 2.1 mmol/L (P&lt;0.001); 39% of patients had a serum phosphorus level greater than 2.1 mmol/L. [Block, 1998, 607A,B, 610A,B, 611B-E]
Block GA, Hulbert-Shearon TE, Levin NE, Port FK. Association of serum phosphorus and calcium phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-617.
The factors involved in the pathogenesis of secondary hyperparathyroidism.
Kaplan-Meier survival curves were generated and a log-rank test was used to detect treatment group differences in time to death.
Baseline CAC score was a significant predictor of mortality in hemodialysis patients.
Figure shows multivariable adjusted survival by baseline CAC score; variables included age, race, gender, and diabetes. The P-value represents statistical significance across 3 stratifications based on baseline CAC:
CAC = 0 (Red Line)
CAC 1-400 (Blue Line)
CAC ≥400 (Green Line)
Subjects with no evidence of CAC (CAC=0) had a significantly lower mortality rate (3.3/100 patient years, CI 0.4-6.1) compared to subjects with a CAC score 1-400 (7.0/100 patient years, CI 2.7-11.4) and those with a CAC score &gt;400 (14.7/100 patient years, CI 8.1-21.4) (P=0.002).
After multivariable adjustment, the presence of a baseline CAC score &gt;400 remained significantly associated with increased mortality (HR=4.5, P=0.016, CI 1.33-15.14).
Key Point: Careful management of calcium, phosphorus, and lipids is required to reduce risk in patients with Stage 5 CKD.
The National Kidney Foundation (NKF), as part of its ongoing clinical practice guidelines, has established goals for the management of calcium and phosphorus levels in patients with stage 5 chronic kidney disease (CKD). Previously, Block and associates also set forth goals for these levels. The long-term goal for serum phosphorus is 3.0 to 5.0 mg/dL and that for calcium-phosphorus product (Ca P) is &lt;55 mg2/dL2. They have also noted that treatment with agents that accumulate and cause toxicity should be avoided. [Block, 2000, 318A] Llach has suggested that the calcium level in the dialysate bath be adjusted to meet the needs of the individual patient. [Llach, 1998, 516A, 517A] London and colleagues have stated that “In the dialysis population, with its greatly increased overall cardiac risk, prevention of calcification and its progression must be a primary goal.” [London, 2000, 781A] These investigators have recommended the use of calcium-free phosphate binders.
Patients with CKD should be placed in the highest National Cholesterol Education Program (NCEP) coronary heart disease (CHD) risk category and their low-density-lipoprotein cholesterol (LDL-C) target should be &lt;100 mg/dL. Specific goals for high-density-lipoprotein cholesterol (HDL-C) and triglycerides (TG) are not stated in the National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF K/DOQI) dyslipidemia guidelines. However, they do indicate that patients with very high TG (500 mg/dL) should be treated to reduce TG levels &lt;500 mg/dL; furthermore, patients with TG 200 mg/dL and non-HDL-C 130 mg/dL should be treated to reduce non-HDL-C &lt;130 mg/dL. [NKF K/DOQI, 2003, S39]
Block GA. Prevalence and clinical consequences of elevated Ca P product in hemodialysis patients. Clin Nephrol. 2000;54:318-324.
Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? Am J Kidney Dis. 1998;32:514-518.
London GM, Pannier B, Marchais SJ, Guerin AP. Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol. 2000;11:778-783.
National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 3):S1-S91.